恶性瘤风险指数与卵巢瘤中的组织病理发现之间的相关性
Sadia Parween1, Poonam Poonam1, Amrita Amrita1
1Department of Obstetrics and Gynaecology, IGIMS, Patna, Bihar, India.
Journal of family medicine and primary care
|October 3, 2025
概括
恶性瘤风险指数 (RMI) 准确诊断卵巢瘤,优于像CA-125这样的个体标志物. 这有助于及时转诊,以实现卵巢癌的最佳手术治疗.
科学领域:
- 妇科 妇科 妇科 妇科
- 在瘤学瘤学.
- 诊断成像 诊断成像 诊断成像
背景情况:
- 卵巢瘤是一个常见的妇科问题,预计到2022年全球癌症死亡人数将超过800万.
- 恶性瘤风险指数 (RMI) 结合了超声波得分,更年期状态和CA-125水平来评估恶性瘤.
研究的目的:
- 评估RMI 3在识别卵巢瘤中的诊断准确性.
- 将RMI 3的疗效与个别诊断指标进行比较.
主要方法:
- 一项前性观察性研究,涉及86名患者一年.
- 患者接受了超声波,CA-125测试和RMI 3计算.
- 拉巴切除术后的组织病理学分析被用于关联RMI得分.
主要成果:
- RMI评分 (截止值225) 显示高特异性 (90.6%) 和积极的预测值 (70.0%).
- 超声波 (USG) 评分显示高灵敏度 (86.4%) 和负预测值 (94.6%).
- 无论是RMI和USG分数都实现了类似的诊断准确率83.7%.
结论:
- 与单个标志物相比,RMI是诊断卵巢瘤的有效工具,具有较高恶性瘤的可能性.
- 为了改善患者管理,RMI促进及时转诊至妇科瘤中心.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...